EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Cell surface marker-based capture of neoantigen-reactive CD8 + T-cell receptors from metastatic tumor digests

Praveen D Chatani, Frank J Lowery iD, Neilesh B Parikh, Kyle J Hitscherich, Rami Yossef, Victoria Hill, Jared J Gartner, Biman Paria, Maria Florentin, Satyajit Ray, Alakesh Bera, Maria Parkhust und 3 weitere

Journal for ImmunoTherapy of Cancer · 2023-05 · 11 (5) · e006264

DOI: 10.1136/jitc-2022-006264 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 31.05.2023. Verfasst von Praveen D Chatani und 14 weiteren Autor:innen. Beteiligte Einrichtung: Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Antigens, Neoplasm, Neoplasms. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cellular immunotherapies using autologous tumor-infiltrating lymphocytes (TIL) can induce durable regression of epithelial cancers in selected patients with treatment-refractory metastatic disease. As the genetic engineering of T cells with tumor-reactive T-cell receptors (TCRs) comes to the forefront of clinical investigation, the rapid, scalable, and cost-effective detection of patient-specific neoantigen-reactive TIL remains a top priority.

Methods

We analyzed the single-cell transcriptomic states of 31 neoantigen-specific T-cell clonotypes to identify cell surface dysfunction markers that best identified the metastatic transcriptional states enriched with antitumor TIL. We developed an efficient method to capture neoantigen-reactive TCRs directly from resected human tumors based on cell surface co-expression of CD39, programmed cell death protein-1, and TIGIT dysfunction markers (CD8 + TIL TP ).

Results

TIL TP TCR isolation achieved a high degree of correlation with single-cell transcriptomic signatures that identify neoantigen-reactive TCRs, making it a cost-effective strategy using widely available resources. Reconstruction of additional TIL TP TCRs from tumors identified known and novel antitumor TCRs, showing that at least 39.5% of TIL TP TCRs are neoantigen-reactive or tumor-reactive. Despite their substantial enrichment for neoantigen-reactive TCR clonotypes, clonal dynamics of 24 unique antitumor TIL TP clonotypes from four patients indicated that most in vitro expanded TIL TP populations failed to demonstrate neoantigen reactivity, either by loss of neoantigen-reactive clones during TIL expansion, or through functional impairment during cognate neoantigen recognition.

Conclusions

While direct usage of in vitro-expanded CD8 + TIL TP as a source for cellular therapy might be precluded by profound TIL dysfunction, isolating TIL TP represents a streamlined effective approach to rapidly identify neoantigen-reactive TCRs to design engineered cellular immunotherapies against cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigens, NeoplasmNeoplasmsHumansCD8-Positive T-LymphocytesReceptors, Antigen, T-CellLymphocytes, Tumor-Infiltrating

Stichwörter der Autor:innen

CD8-Positive T-LymphocytesCell EngineeringImmunity, CellularImmunotherapyLymphocytes, Tumor-Infiltrating

Substanzen

Antigens, NeoplasmReceptors, Antigen, T-Cell

Autor:innen und Institutionen

  • Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA sri.krishna@nih.gov frank.lowery@nih.gov sar@mail.nih.gov.

ORCID-Profile: Frank J Lowery, Paul Robbins, Sri Krishna

Förderung

  • National Institutes of Health

Zitieren

APA

Chatani, P. D., Lowery, F. J., Parikh, N. B., Hitscherich, K. J., Yossef, R., Hill, V., Gartner, J. J., Paria, B., Florentin, M., Ray, S., Bera, A., Parkhust, M., Robbins, P., Krishna, S., & Rosenberg, S. A. (2023). Cell surface marker-based capture of neoantigen-reactive CD8 + T-cell receptors from metastatic tumor digests. Journal for ImmunoTherapy of Cancer, 11(5), e006264. https://doi.org/10.1136/jitc-2022-006264

Vancouver

Chatani PD, Lowery FJ, Parikh NB, Hitscherich KJ, Yossef R, Hill V, et al. Cell surface marker-based capture of neoantigen-reactive CD8 + T-cell receptors from metastatic tumor digests. Journal for ImmunoTherapy of Cancer. 2023;11(5):e006264. doi:10.1136/jitc-2022-006264

BibTeX
@article{Chatani2023,
  author = {Chatani, Praveen D and Lowery, Frank J and Parikh, Neilesh B and Hitscherich, Kyle J and Yossef, Rami and Hill, Victoria and Gartner, Jared J and Paria, Biman and Florentin, Maria and Ray, Satyajit and Bera, Alakesh and Parkhust, Maria and Robbins, Paul and Krishna, Sri and Rosenberg, Steven A},
  title = {Cell surface marker-based capture of neoantigen-reactive CD8 + T-cell receptors from metastatic tumor digests},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2023},
  volume = {11},
  number = {5},
  pages = {e006264},
  doi = {10.1136/jitc-2022-006264}
}
Kostenlos starten →